Alexander Staller, DO
Pulmonary Disease · Omaha, NENPI 1497101919
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.9% of the total across 102 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by United Therapeutics Corporation at 33.4% of the total. 2025 is the largest year on record at $1,312, 7.4 times the $178 reported in 2022.
Across 102 payments — averaging $29.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$1K
- AstraZeneca$752
- Merck$239
- Actelion Pharmaceuticals US, Inc.$142
- Insmed, Inc.$112
- Jazz Pharmaceuticals Inc.$108
- plus $676 from 17 others
What the payments were for
- Food & beverage$2,86094%
- Education$1856%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 18 | $1,016 |
| AstraZeneca | 28 | $752 |
| Merck | 8 | $239 |
| Actelion Pharmaceuticals US, Inc. | 4 | $142 |
| Insmed, Inc. | 5 | $112 |
| Jazz Pharmaceuticals Inc. | 6 | $108 |
| Mallinckrodt Hospital Products Inc. | 1 | $100 |
| Boehringer Ingelheim | 5 | $100 |
| Regeneron Healthcare Solutions, Inc. | 5 | $76 |
| Amgen | 3 | $50 |
| Grifols USA, LLC | 2 | $49 |
| Bayer | 2 | $45 |
| Electromed, Inc. | 3 | $43 |
| Avadel CNS Pharmaceuticals, LLC | 2 | $33 |
| Pharming Healthcare, Inc. | 1 | $31 |
| Mylan Specialty L.p. | 2 | $30 |
| Harmony Biosciences LLC | 1 | $22 |
| Verona Pharma, Inc. | 1 | $19 |
| Olympus America Inc. | 1 | $18 |
| Viatris Specialty LLC | 1 | $16 |
| Philips North America LLC | 1 | $16 |
| GSK | 1 | $14 |
| Axsome Therapeutics, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,045 in reported general payments places this provider in the 55th percentile of 81 pulmonary disease providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OpsumitMacitentan | 35 | $443,110 |
| Tyvaso DpiTreprostinil | 17 | $381,672 |
| AdempasRiociguat | 23 | $324,536 |
| Orenitram ErTreprostinil Diolamine | 47 | $196,817 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 45 | $49,139 |
| Ambrisentan | 21 | $39,068 |
| Sildenafil Citrate | 73 | $23,611 |
| Pirfenidone | 12 | $11,339 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 18 | $9,493 |
| Tadalafil | 19 | $4,644 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 18 | $409 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit | $142 | $443,11035 claims |
| BayerAdempas | $45 | $324,53623 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $14 | $58,63163 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 81 pulmonary disease providers in Nebraska.
Other pulmonary disease in Omaha
- Stephen RennardOmaha$50K
- Douglas MooreOmaha$40K
- Adam WellsOmaha$26K
- Zachary DepewOmaha$26K
- Michael SanleyOmaha$17K
- Adam HighleyOmaha$15K
- Carolina LandeenOmaha$14K
- Patrick MeyersOmaha$12K
- John DickinsonOmaha$8K
- Palvannanathan GanesanOmaha$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.